PMID- 18785960
OWN - NLM
STAT- MEDLINE
DCOM- 20090326
LR  - 20230124
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 8
IP  - 11
DP  - 2008 Nov
TI  - mTOR, cancer and transplantation.
PG  - 2212-8
LID - 10.1111/j.1600-6143.2008.02391.x [doi]
AB  - One of the most clinically important molecular signalling networks to emerge over 
      the past decade is the mammalian target of rapamycin (mTOR) pathway. mTOR, the 
      protein kinase at the core of this intricate and continually evolving pathway, 
      controls cellular growth and behavior, impacting vital processes from immune 
      reactivity to cancer progression. As researchers, surgeons and physicians in the 
      field of organ transplantation, we have acquired a keen interest in regulating 
      mTOR activity, because this molecule is not only able to block IL-2 signalling in 
      T cells, and thus alloimmune reactivity, it is a critical part of the cellular 
      circuitry which is often constitutively activated in neoplastic cells, leading to 
      the all-too-often occurrence of cancer. Since allograft rejection and the 
      development of cancer lead most lists for causing excess morbidity and mortality 
      in our organ transplant population, a thorough and current understanding of the 
      mTOR pathway becomes essential. In this review, we endeavor to unravel the latest 
      molecular developments in mTOR signalling and use this basic knowledge to 
      generate perspectives on how pharmacologic mTOR intervention may form a balance 
      to impact long-term antidonor immune responses and the development of malignancy 
      in transplant recipients.
FAU - Geissler, Edward K
AU  - Geissler EK
AD  - Department for Surgery, University of Regensburg, Regensburg, Germany. 
      edward.geissler@klinik.uni-regensburg.de
FAU - Schlitt, Hans J
AU  - Schlitt HJ
FAU - Thomas, George
AU  - Thomas G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20080910
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of 
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
RN  - 0 (CRTC2 protein, human)
RN  - 0 (Interleukin-2)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (Proteins)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Disease Progression
MH  - *Gene Expression Regulation, Neoplastic
MH  - Graft Rejection
MH  - Humans
MH  - Interleukin-2/metabolism
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Models, Biological
MH  - Multiprotein Complexes
MH  - Neoplasms/*complications/*etiology/metabolism
MH  - Neovascularization, Pathologic
MH  - Organ Transplantation/*adverse effects
MH  - Protein Kinases/*physiology
MH  - Proteins
MH  - Signal Transduction
MH  - T-Lymphocytes/metabolism
MH  - TOR Serine-Threonine Kinases
MH  - Transcription Factors/metabolism
RF  - 35
EDAT- 2008/09/13 09:00
MHDA- 2009/03/27 09:00
CRDT- 2008/09/13 09:00
PHST- 2008/09/13 09:00 [pubmed]
PHST- 2009/03/27 09:00 [medline]
PHST- 2008/09/13 09:00 [entrez]
AID - S1600-6135(22)02984-7 [pii]
AID - 10.1111/j.1600-6143.2008.02391.x [doi]
PST - ppublish
SO  - Am J Transplant. 2008 Nov;8(11):2212-8. doi: 10.1111/j.1600-6143.2008.02391.x. 
      Epub 2008 Sep 10.